This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Xenazine

Valeant Pharmaceuticals International, Inc.

Drug Names(s): tetrabenazine, Nitoman (EU)

Description: Tetrabenazine (marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe) is a dopamine-depleting drug that is closely related to the antipsychotics and has a similar mechanism of action. It specifically targets the vesicular monoamine transporter 2 (VMAT2). VMAT2 is located primarily in the brain and sympathetic neurons.

Tetrabenazine has two modes of action; it depletes pre-synaptic stores of monoamines and has a postsynaptic receptor blocking action. These effects on the monoamine dopamine signal transduction pathways contribute to its activity. The culmination of this activity is to modulate the transmission of electrical signals in the brain involving the control of movement.

Deal Structure: Xenazine was originallydeveloped by LifeHealth Limited. In 1996, Cambridge Laboratories acquired global rights to Xenazine. Prestwick Pharmaceuticals licensed the rights to market and commercialize tetrabenazine in North America from Cambridge.

Cambridge and Opi SA
In 2003, Cambridge entered into an exclusive licensing agreement with Opi SA in France for the marketing and distribution rights of Xenazine.

Opi SA and EUSA Pharmaceuticals
In March 2007, EUSA Pharmaceuticals acquired Opi SA.

Cambridge and Temmler Pharmaceuticals
In June 2006, Cambridge announced that it has signed an agreement with Temmler Pharmaceuticals giving them exclusive marketing and distribution rights of Nitoman in Germany and Austria.

OVATION and Prestwick/Biovail
In September 2008, OVATION Pharmaceuticals announced that it has acquired from Prestwick Pharmaceuticals the exclusive license in the United States to commercialize Xenazine for the treatment of...See full deal structure in Biomedtracker

Partners: H. Lundbeck A/S UCB SA Lupin Limited Jazz Pharmaceuticals plc


Xenazine News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug